Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atorvastatin + sodium bicarbonate is an investigational combination therapy being evaluated by Taipei Medical University Shuang Ho Hospital for the treatment of autosomal dominant polycystic kidney disease (ADPKD). This therapeutic regimen combines atorvastatin, a standard HMG-CoA reductase inhibitor (statin), with sodium bicarbonate, an oral alkalizing agent. The rationale behind this combination is based on evidence that metabolic acidosis, which frequently occurs as chronic kidney disease (CKD) progresses, may limit the anti-inflammatory and Reno-protective effectiveness of statins while increasing their potential toxicity. By co-administering sodium bicarbonate to correct acidosis, the treatment aims to optimize the efficacy of atorvastatin in slowing kidney cyst growth and preserving renal function in adult ADPKD patients with Stage 1-3a CKD.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atorvastatin + sodium bicarbonate.